Journal article
The VEGF signaling pathway in cancer: The road ahead
SA Stacker, MG Achen
Chinese Journal of Cancer | Published : 2013
Abstract
The vascular endothelial growth factor (VEGF) family of soluble protein growth factors consists of key mediators of angiogenesis and lymphangiogenesis in the context of tumor biology. The members of the family, VEGF-A (also known as VEGF), VEGF-B, VEGF-C, VEGF-D, and placenta growth factor (PlGF), play important roles in vascular biology in both normal physiology and pathology. The generation of a humanized neutralizing antibody to VEGF-A (bevacizumab, also known as Avastin) and the demonstration of its benefit in numerous human cancers have confirmed the merit of an anti-an giogenesis approach to cancer treatment and have validated the VEGF-A signaling pathway as a therapeutic target. Other..
View full abstractGrants
Funding Acknowledgements
This work was funded partly by a program grant from the National Health and Medical Research Council of Australia (NH&MRC). SAS and MGA are supported by Senior Research Fellowships from the NH&MRC. SAS would like to acknowledge the support of the Pfizer Australia Fellowship. SAS and MGA are consultants for Vegenics Ltd, a company which develops inhibitors of angiogenesis.